Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vincent T. Ma has a total of 363 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data 1 from Longitudinal Phenotyping of Circulating Tumor Cells Using a Scalable Deep Learning Framework

    by Matthew L. Bootsma, Marina N. Sharifi, Jamie M. Sperger, Jennifer L. Schehr, William M. Stump, Hamza Bakhtiar, Matthew Mannino, Viridiana Carreno, Alex H. Chang, Charlotte Stahlfeld, et al.

    All supplementary Figures and tables.

  • Open Access

    Intratumoral Immunotherapy—The Future of Treating Merkel Cell Carcinoma?

    by Nayonika Pande, Justin C. Moser, Sanjay Chandrasekaran, Andrew S. Brohl, Rajan P. Kulkarni, Vincent T. Ma

    Merkel cell carcinoma (MCC) represents a rare but highly aggressive neuroendocrine skin cancer with limited systemic therapy options for patients who fail or are ineligible for immune checkpoint inhibitors (ICIs). Intratumoral (IT) immunotherapy has emerged as a promising strategy, leveraging the accessibility of tumor lesions and their inherent capacity to trigger immune responses, known as abscopal effects. This review synthesizes the current evidence on IT approaches in MCC, including Toll-like receptor agonists, cytokines, and oncolytic viruses, and highlights their distinct mechanisms of action, while emphasizing the critical need for standardized radiographic response assessment of injected and non-injected lesions. Inconsistent documentation of abscopal responses has hindered quantification of IT therapy’s systemic potential, particularly in a disease where one-third of patients present with metastases and distant relapse is common. We outline MCC-specific rationale for routine lesion-level tracking, and recommendations for IT trial designs and objectives. Rigorous assessments of abscopal data will clarify IT’s role as both rescue therapy and an ICI partner, potentially transforming outcomes in this refractory MCC.

  • Open Access

    Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced Melanoma

    by Alyssa K. Steimle, Amir M. Forati, Alice Y. Zhou, Trevor McCracken, Meena M. Hosny, Golbarg Rahimi, Janmesh D. Patel, Caroline Burkey, Jessica Caraway, Taylor Huppe, et al.

    Background/Objectives: ctDNA is evolving as an important biomarker for prognostic assessment in advanced melanoma. However, the utility of ctDNA monitoring during concurrent ICI with RT remains incompletely explored. Methods: In this multicenter retrospective study, patients with unresectable stage III/IV melanoma treated with ICI and palliative RT were identified. Patients had retrospectively collected, tumor-informed, exome-based, ctDNA monitoring within 3 months following RT. Results: A total of 50 patients treated with ICI and palliative RT were analyzed. Compared with ctDNA clearance, ctDNA detectable and increasing was associated with worse OS (adjusted HR 2.52, 95% CI 1.20–5.29; p = 0.015), whereas ctDNA detectable and decreasing was not significantly different from ctDNA clearance (adjusted HR 1.58, 95% CI 0.69–3.65; p = 0.282). One-year OS was 87.5% with persistently undetectable ctDNA, 83.3% for ctDNA clearance, 46.3% for detectable and decreasing ctDNA, and 21.4% for detectable and increasing ctDNA. In a multivariable analysis, detectable and increasing ctDNA was associated with worse OS compared with ctDNA clearance (HR 2.52, 95% CI, 1.20–5.29, p = 0.015). Conclusions: Among patients with advanced melanoma treated with ICI and palliative RT, ctDNA clearance is associated with significantly improved OS compared to patients with detectable and increasing ctDNA within 3 months following RT. Ongoing prospective studies are needed to understand the role of ctDNA in this population.

  • Longitudinal Phenotyping of Circulating Tumor Cells Using a Scalable Deep Learning Framework

    by Matthew L. Bootsma, Marina N. Sharifi, Jamie M. Sperger, Jennifer L. Schehr, William M. Stump, Hamza Bakhtiar, Matthew Mannino, Viridiana Carreno, Alex H. Chang, Charlotte Stahlfeld, et al.

    Purpose: Circulating tumor cells (CTC) provide a minimally invasive window into metastatic disease and treatment response, but their clinical utility has been constrained by manual, subjective, low-throughput identification in multichannel fluorescence microscopy data. Experimental Design: To address this limitation, we developed and clinically validated the System for Enhanced Evaluation of Tumor Cells (SEE-TC), a deep learning approach for scalable, reproducible phenotyping of individual circulating cells. SEE-TC was developed and evaluated on more than 8.5 million cells from 3,386 blood samples spanning six cancer types, enabling generalization across heterogeneous imaging conditions, staining panels, and acquisition platforms. Results: SEE-TC achieved single-cell segmentation accuracy on par with humans, learned biologically relevant latent cellular representations that correlate with established morphologic and immunofluorescent biomarkers, and reliably distinguished CTCs from background populations without reliance on arbitrary thresholds. When applied longitudinally, SEE-TC provides a quantitative, patient-level readout of CTC burden over time, which was significantly associated with worse overall survival across multiple cancer types. Conclusions: To our knowledge, this is the first fully automated artificial intelligence approach to single-cell segmentation and CTC phenotyping. By transforming CTC analysis from a human-dependent task into a scalable and reproducible digital assay, SEE-TC enables high-fidelity longitudinal monitoring of tumor burden and supports broader clinical deployment of CTC-based liquid biopsies in precision oncology. It is currently being deployed to identify CTCs and quantify target expression for both prognostic and predictive biomarker evaluation in multiple prospective clinical trials on a commercial platform.


  • Open Access

    Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced Melanoma

    by Alyssa K. Steimle, Amir M. Forati, Alice Y. Zhou, Trevor McCracken, Meena M. Hosny, Golbarg Rahimi, Janmesh D. Patel, Caroline Burkey, Jessica Caraway, Taylor Huppe, et al.

    CtDNA is evolving as an important biomarker for ICI treatment response assessment in advanced melanoma. However, the utility of ctDNA monitoring during concurrent ICI with RT remains incompletely explored. In this multicenter, retrospective study, patients with unresectable stage III/IV melanoma treated with ICI and palliative RT were identified. Patients had retrospectively collected, tumor-informed, exome-based, ctDNA monitoring within 3 months following RT. 50 patients treated with ICI and palliative RT were analyzed. Patients with ctDNA clearance had significantly longer OS (HR 2.10, 95% CI 1.16-3.80, p=0.014) compared to those with increasing or decreasing and detectable ctDNA following RT. One-year OS was 85.9% with ctDNA clearance, 30.6% with decreasing ctDNA, and 22.0% for increasing ctDNA. In a multivariable analysis, both decreasing and increasing ctDNA were associated with worse OS compared with ctDNA clearance (HR 5.08 [95% CI, 1.26–20.48, p=0.022] and HR 9.83 [95% CI, 2.69–35.94, p< 0.001], respectively). Among patients with advanced melanoma treated with ICI and palliative RT, ctDNA clearance is associated with significantly improved OS compared to patients with detectable ctDNA within 3 months following RT. Ongoing studies are needed to understand the role of ctDNA in this population.

  • Open Access

    Updates on intratumoral therapies in melanoma

    by Vincent T. Ma, Alyssa K. Steimle, Janmesh D. Patel, Caroline Burkey, Justin C. Moser, Asad Javed, Hibba Tul Rehman, Mustafa Ege Seker, Alexander Birbrair, Orhan S. Ozkan, et al.

    Intratumoral therapies provide an opportunity for novel strategies in the management of advanced melanoma. These approaches deliver concentrated doses of therapeutic immune agents directly into individual tumor(s), achieving local tumor control and induction of systemic antitumor immune responses while minimizing the risk of immune‐related adverse events. Talimogene laherparepvec, a genetically modified herpes simplex virus type 1–encoding granulocyte‐macrophage colony–stimulating factor, was the first oncolytic viral therapy approved in a solid tumor indication. In pivotal trials of patients with melanoma, talimogene laherparepvec demonstrated durable responses. Building on this paradigm, next‐generation oncolytic agents incorporate additional genetic modifications, such as fusogenic proteins and immunostimulatory transgenes, to enhance local cytotoxicity and systemic immune priming. Clinical studies of intratumoral, injectable agents since 2010 have evaluated monotherapy as well as combination strategies with immune checkpoint inhibitors, revealing improved response rates and durable remissions, including in patients with immune checkpoint inhibitor‐resistant disease. This review summarizes the mechanistic rationale, preclinical evidence, and clinical development of intratumoral therapies in melanoma. Key trial outcomes, safety profiles, and practical considerations for administration are discussed. Emerging trends include image‐guided visceral injection, combinatorial regimens, and the integration of intratumoral therapy in the neoadjuvant setting. As these therapies evolve, intratumoral approaches may expand their role in melanoma management, bridging locoregional tumor control with systemic immune activation and complementing existing systemic treatments.


  • Open Access

    Supplementary Figure 7 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

    by George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin, Griffin L. Budde, Andrew Poklepovic, Bently P. Doonan, Meghan J. Mooradian, Ryan J. Sullivan, Vincent T. Ma, et al.

    Distribution of lead time between ctDNA detection and imaging-confirmed recurrence using the first ctDNA-positive sample prior to recurrence. Each dot represents an individual patient with green dots representing patients who became ctDNA-positive and whose initial post-positivity imaging remained negative with recurrence confirmed on subsequent imaging.

  • Open Access

    Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

    by George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin, Griffin L. Budde, Andrew Poklepovic, Bently P. Doonan, Meghan J. Mooradian, Ryan J. Sullivan, Vincent T. Ma, et al.

  • Open Access

    Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

    by George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin, Griffin L. Budde, Andrew Poklepovic, Bently P. Doonan, Meghan J. Mooradian, Ryan J. Sullivan, Vincent T. Ma, et al.

    A, Kaplan–Meier RFS curves stratified by ctDNA status among patients who received adjuvant systemic therapy. Anytime ctDNA positivity was associated with significantly inferior RFS. B, Kaplan–Meier RFS curves stratified by ctDNA status among patients who did not receive adjuvant therapy, showing a similar strong association between ctDNA positivity and recurrence. C, Sankey diagram illustrating ctDNA dynamics after systemic therapy initiation among 53 patients with ≥1 on-treatment ctDNA timepoint. Of the 8 patients who recurred, 2 exhibited persistent ctDNA positivity or converted from ctDNA-negative to ctDNA-positive despite treatment. A subset demonstrated transient clearance before recurrence.

  • Open Access

    Supplementary Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

    by George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin, Griffin L. Budde, Andrew Poklepovic, Bently P. Doonan, Meghan J. Mooradian, Ryan J. Sullivan, Vincent T. Ma, et al.

    Representativeness of the study participants